Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study

British Journal of Haematology

Volumn 122, Issue 3, 2003, Pages 394-403

  Hedenus, Michael ^a   Adriansson, Magnus ^b   San Miguel, Jesus ^c   Kramer, Mark H H ^d   Schipperus, Martin R ^e   Juvonen, Eeva ^f   Taylor, Kerry ^g   Belch, Andrew ^h   Altés, Albert ⁱ   Martinelli, Giovanni ^j   Watson, David ^k   Matcham, James ^k   Rossi, Gregory ^l   Littlewood, Timothy J ^m  

^a SUNDSVALL HOSPITAL   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d MEANDER MEDICAL CENTER   (Netherlands)

^e LEYENBURG HOSPITAL   (Netherlands)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g MATER HOSPITAL   (Australia)

^h CROSS CANCER INSTITUTE   (Canada)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k AMGEN LTD   (United Kingdom)

^l AMGEN INC   (United States)

^m OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Anaemia; Cancer; Erythropoietin; Lymphoma; Myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FEVER; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOMA; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANEMIA; BLOOD TRANSFUSION; DIARRHEA; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FATIGUE; FEMALE; FEVER; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NAUSEA; QUALITY OF LIFE;

EID: 0041627742     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04448.x     Document Type: Article

References (39)

1. Abels, R.I. (1992) Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Seminars in Oncology, 19, 29-35.
2. Abels, R.I. Larholt, K.M., Krantz, K.D. & Bryant, E.C. (1991) Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. In: Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. Proceedings of the Beijing Symposium (ed. by M.J. Murphy. Jr). pp. 121-142. Alpha-Med Press. Dayton: OH.
3. Barlogie, B. & Beck, T. (1993) Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells, 11, 88-94.
4. Berndt, E., Kallich, J., Xu, X., Erder, M.E., Glaspy, J. & Lee, H. (2002) Reductions in anemia and fatigue are associated with improvements in productivity. Blood, 100, 876a.
5. Bohlius, J.F., Langensiepen, S., Schwarzer, G. & Engert, A. (2002) Epoietin in the treatment of malignant disease: a comprehensive meta-analysis. Blood, 100, 870a.
6. Cabanillas, F., Burke, J.S., Smith. T.L., Moon, T.E., Butler, J.J. & Rodriquez, V. (1978) Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. Archives of Internal Medicine, 138, 413-418.
7. Casadevall, N. (1998) Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Seminars in Oncology, 25, 12-18.
8. Cazzola, M., Messinger, D., Battistel, V., Bron, D., Cimino, R., Enller-Ziegler, L., Essers, U., Greil, R., Grossi, A., Jäger, G., LeMevel, A., Najman, A., Silingardi, V., Spriano, M., van Hoof, A. & Ehmer, B. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood, 86, 4446-4453.
9. Cella, D. (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Seminars in Hematology, 34, 13-19.
10. Cella, D., Lai, J.-S., Chang, C.-H., Peterman, A. & Slavin, M. (2002) Fatigue in cancer patients compared with fatigue in the general United States population. Cancer, 94, 528-538.
11. Coiffier, B. (2000) The impact and management of anaemia in haemotological malignancies. Medical Oncology, 17, s2-s10.
12. Dammacco, F., Silvestris, F., Castoldi, G.L., Grassi, B., Bernasconi, C., Nadali, G., Perona, G., De Laurenzi, A., Torelli, U., Ascari, E., Rossi Ferrini, P.L., Caligaris-Cappio, F., Pileri, A. & Resegotti, L. (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. International Journal of Clinical and Laboratory Research, 28, 127-134.
13. Dammacco, F., Castoldi, G. & Rödjer, S. (2003) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. British Journal of Haematology, 113, 172-179.
14. Demetri, G.D., Kris, M., Wade, J., Degos, L., Cella, D. & Procrit Study Group (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Journal of Clinical Oncology, 16, 3412-3425.
15. Egrie, J.C., Grant, J.R., Gillies, D.K., Aoki, K.H. & Strickland, T.W. (1993) The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate Journal, 10, 263.
16. Gabrilove, J.L., Cleeland, C.S., Livingston, R.B., Sarokhan, B., Winer, E. & Einhorn, L.H. (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19, 2875-2882.
17. Garton, J.P., Gertz, M.A., Witzig, T.E., Greipp. P.R., Lust, J.A., Schroeder, G. & Kyle, R.A. (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Archives of Internal Medicine, 155, 2069-2074.
18. Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tcheckmedyian, S., Vadhan-Raj, S. & Procrit Study Group (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Journal of Clinical Oncology, 15, 1218-1234.
19. Glaspy, J.A., Jadeja, J.S., Justice, G., Kessler, J., Richards, D., Schwartzberg, L., Tchekmedyian, N.S., Armstrong, S., O'Byrne, J., Rossi, G. & Colowick, A.B. (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer, 87, 268-276.
20. Groopman, J.E. & Itri, L.M. (1999) Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute, 91, 1616-1634.
21. Hedenus, M., Glaspy, J., Dewey, C., O'Byrne, J., Colowick, A., NESP 990114 & 980290 Study Groups (2001) Dose-response of darbepoetin alfa is similar in anemic patients with solid tumors or lymphoproliferative malignancies, Blood, 98, 297.
22. Hedenus, M., Hansen, S., Taylor, K., Arthur, C., Emmerich, B., Dewey, C., Watson, D., Rossi, G. & Österborg, A. (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. British Journal of Haematology, 119, 79-86.
23. Kalbfleisch, J.D. & Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. pp. 1-316. John Wiley & Sons, New York.
24. Kallich, J., Tchekmedyian, S., Damiano, A., Shi, J., Black, J. & Erder, M.E. (2002) Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology, 16, 117-124.
25. Kotasek, D., ARANESP 980291 Study Group, Berg, R., Poulsen, E. & Colowick, A. (2000) Randomized, double-blind, placebo-controlled, phase I/II dose finding study of ARANESP™ administered once every three weeks in solid tumor patients. Blood, 96, 294a-295a.
26. Leonard, R.C.F., Hayward, R.L., Prescott, R.J. & Wang, J.X. (1991) The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. Annals of Oncology, 2, 655-662.
27. Littlewood, T.J., Bajetta, E., Nortier, J.W.R., Vercammen, E., Rapoport, B. & Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 2865-2874.
28. Ludwig, H. & Fritz, E. (1998) Anemia in cancer patients. Seminars in Oncology, 25, 2-6.
29. Ludwig, H., Fritz, E., Kotzmann, H., Höcker, P., Gisslinger, H. & Barnas, U. (1990) Erythropoietin treatment of anemia associated with multiple myeloma. New England Journal of Medicine, 322, 1693-1699.
30. Macdougall, I.C., Gray, S.J., Elston, O., Breen, C., Jenkins, B., Browne, J. & Egrie, J. (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Journal of the American Society of Nephrology, 10, 2392-2395.
31. Mittelman, M., Zeidman, A., Fradin, Z., Magazanik, A., Lewinski, U.H. & Cohen, A. (1997) Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematologica, 98, 204-210.
32. Nowrousian, M.R. (1998) Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Medical Oncology, 15, s19-s28.
33. Österborg, A., Boogaerts, M.A., Cimino, R., Essers, U., Holowiecki, J., Juliusson, G., Jäger, G., Najman, A., Peest, D. & European Study Group of Erythropoietin (Epoetin beta) Treatment in Multiple Myeloma and Non-Hodgkin's lymphoma (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a randomized multicenter study. Blood, 87, 2675-2682.
34. Österborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., Messinger, D. & Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. Journal of Clinical Oncology, 20, 2486-2494.
35. Rizzo, J.D., Lichtin, A.E., Woolf, S.H., Seidenfeld, J., Bennett, C., Cella, D., Djulbegovic, B., Goode, M.J., Jakubowski, A.A., Lee, S.J., Miller, C.B., Rarick, M.U., Regan, D.H., Browman, G.P. & Gordon, M.S. (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Journal of Clinical Oncology, 20, 4083-4107.
36. Silvestris, F., Romito, A., Fanelli, P., Vacca, A. & Dammacco, F. (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Annals of Hematology, 70, 313-318.
37. Straus, D.J., Gaynor, J.J., Myers, J., Merke, D.P., Caravelli, J., Chapman, D., Yahalom, J. & Clarkson, B.D. (1990) Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. Journal of Clinical Oncology, 8, 1173-1186.
38. Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., Siena, S., Gateley, J., Tomita, D., Colowick, A.B. & Musil, J. (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94, 1211-1220.
39. Walker, R.H. (1987) Special report: transfusion risks. American Journal of Clinical Pathology, 88, 374-378.